What to know: the 4 peptides FDA just cleared The evidence for the newly approved peptides, and the names of the FDA advisory panel members who have a financial interest in the votes they just cast to approve them
Research findings from these controlled studies contribute to understanding melanocortin receptor agonists and their diverse physiological effects, though all applications remain strictly within research contexts without therapeutic implications
Triple agonists targeting GLP-1, GIP, and glucagon are in development, requiring devices that can handle their specific formulations
To better elucidate the action of irisin and confirm whether it mediates exendin-4 effects, it would also be interesting to perform experiments with simultaneous silencing of the FNDC5 gene
If you applied that argument more generally, it would prevent the government from banning almost any substance that people widely demand. While health experts like Knoepfler remain unconvinced by the harm-reduction argument when it comes to making peptides more accessible, changing the FDAs stance would serve the health department leaderships attempts to brand the agency as pro-innovation and anti-bureaucracy
